CELL INTELLIGENCE · 肿瘤细胞治疗研究

复发性胰腺导管腺癌中生物标志物驱动的免疫治疗与过继细胞治疗

Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.

工程化免疫细胞与细胞外囊泡靶向实体瘤免疫治疗中的肿瘤微环境屏障

Engineered immune cells and extracellular vesicles target tumour microenvironment barriers in solid tumour immunotherapy.

胰腺癌新兴嵌合抗原受体免疫细胞治疗：机制、临床进展与未来展望

Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives.

一种新型靶向 MICB 的 CAR-NK 细胞用于胰腺癌治疗

A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.

Neoleukin-2/15 装甲 CAR-NK 细胞通过 c-Myc/NRF1 激活在实体瘤中维持优越的治疗效果

Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.

CAR 介导的细胞免疫治疗在胰腺癌临床应用中的实力与前景

The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.

GPR116 受体通过 Gαq/HIF1α/NF-κB 信号通路调节 NK 细胞抗肿瘤功能并作为潜在免疫检查点

GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint.

我们的数据表明，GPR116 受体对 NK 细胞功能具有负向作用，而下调 NKG2D-CAR-NK92 细胞中的 GPR116 受体可增强抗肿瘤活性，这为提升 CAR NK 细胞的抗肿瘤效率提供了新思路。

细胞免疫治疗用于胰腺癌的进展与前景

Progress and prospects for use of cellular immunotherapy in pancreatic cancer.

STING 激动剂 cGAMP 增强 CAR-NK 细胞抗胰腺癌的抗肿瘤活性

STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.

2009 至 2021 年 CAR-T 细胞的文献计量学与知识图谱分析

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。